# A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

> **NCT05861674** · PHASE2 · COMPLETED · sponsor: **Huahui Health** · enrollment: 101 (actual)

## Conditions studied

- Chronic Hepatitis Delta Virus Infection

## Interventions

- **BIOLOGICAL:** HH-003(20mg/kg)
- **BIOLOGICAL:** HH-003(10mg/kg)
- **DRUG:** TAF

## Key facts

- **NCT ID:** NCT05861674
- **Lead sponsor:** Huahui Health
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-16
- **Primary completion:** 2024-07-18
- **Final completion:** 2025-06-21
- **Target enrollment:** 101 (ACTUAL)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05861674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05861674, "A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05861674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*